logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Glyco Era Ag Announces New Investor, Appoints Industry Veteran Greg Fralish As Chief Business Officer

Jan 05, 2024•almost 2 years ago

Position

Chief Business Officer

Company

GlycoEra AG

Greg Fralish
WädenswilBiotechnology

Description

GlycoEra AG, a pioneering company advancing a pipeline of extracellular protein degraders for the treatment of autoimmune disorders, today announced the expansion of its Series A financing with an investment from Bristol Myers Squibb . GlycoEra also announced the addition of industry veteran Greg Fralish, Ph.D, as Chief Business Officer to expand and strengthen its leadership team.

Company Information

Company

GlycoEra AG

Location

Wädenswil, Zurich, Switzerland

About

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months